share_log

Aptar Expands Pharmaceutical Services; Announces Exclusive Collaboration Between Aptar Pharma And Fluidda

Benzinga Real-time News ·  2022/09/22 08:37

Nanopharm, an Aptar Pharma company and leader in contract research and development services for orally inhaled and nasal drug products (OINDPs), today announced an exclusive collaboration with Fluidda, a leader in the field of Functional Respiratory Imaging. The companies will leverage their respective proprietary technology platforms to help accelerate U.S. Food & Drug Administration (FDA) approvals for orally inhaled generic products (OIDPs) via the alternative bioequivalence pathway. Nanopharm was acquired by Aptar (NYSE:ATR) in 2019, as part of the company's strategy to expand its services offerings and partner with pharmaceutical companies earlier in the drug development process.

This press...

これらの内容は、情報提供及び投資家教育のためのものであり、いかなる個別株や投資方法を推奨するものではありません。 更に詳しい情報
    コメントする